33 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
24 Aug 23
Regulation FD Disclosure
7:00am
is an oral candidate, a well-defined clinical target, and clinical & regulatory programs underpinned by a biomarker strategy. The How: Strong community … profile with competitive differentiation Well considered pricing strategy Considerations for Potential Pharma Partners
17 Confidential "Conversations
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
12 Sep 23
Other Events
7:00am
, SHINE, SPARC and SEQUEL to drive program design Getting to Goal: Phase 2 Program Informs Phase 3 & Regulatory Strategy Preliminary Phase 3 … Considerations Preliminary Biomarker Strategy Considerations
20 $0 $10 $20 $30 $40 $50 $60 $70 $80 $90 $100 2016 2017 2018 2019 2020 2021 2022 $15 $7 $17 $3 $81
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
and validate our operational strategy,” commented Lisa Ricciardi, president and CEO of Cognition Therapeutics. “We completed enrollment for our SEQUEL
DEF 14A
7rjrob7h9nqjoeke0
25 Apr 22
Definitive proxy
5:28pm
424B4
f5og92u2myu0o
14 Nov 22
Prospectus supplement with pricing info
6:02am
S-1
EX-10.18
t8x8boj16q20ht
19 Jul 21
IPO registration
7:02am
DRS
EX-10.16
befsa50f9daw4j4
7 May 21
Draft registration statement
12:00am
S-1
t1mnze
19 Jul 21
IPO registration
7:02am
DRS/A
mhyl10
23 Jun 21
Draft registration statement (amended)
12:00am
424B4
zume723150c32aaxe
12 Oct 21
Prospectus supplement with pricing info
4:11pm
DRS
bus8ubav5j
7 May 21
Draft registration statement
12:00am
10-K
2a2dedmxt
30 Mar 22
Annual report
7:40am
DRS
gaw ht6gpcnr055u7
20 Oct 22
Draft registration statement
12:00am